By Brian Marckx, CFA

Aethlon Medical (OTC BB:AEMD) continues to attract financing to fund development of their Hemopurifier, reflecting ongoing investor interest.  Since the beginning of the current year Aethlon has raised over $1.6 million in new financing, the most recent of which came in mid-June from the sale of 8.22 million shares of common stock at $0.072/share (80% of the most recent avg 5-day closing price) for gross proceeds of $592k.  The investor also received seven-year warrants to purchase 4.1 million common shares for $0.109 (120% premium to the most recent avg 5-day closing price).   


To access a free copy of the full AEMD research report, please visit Brian Marckx's coverage page at scr.zacks.com.